User account menu

Log in

Breadcrumb

Home
Log In

Log in

Primary tabs

Log in
Reset your password

Username

Password

Leave this field blank

Footer menu

HOME
PRODUCT INFORMATION
TERMS OF USE
PRIVACY POLICY
CONTACT US
PFIZER AUSTRALIA

©2025 Pfizer Australia Pty Ltd. ABN 50 008 422 348. Sydney, Australia. Medical Information: 1800 675 229.
^®Registered trademark. Date of preparation: March 2025. PP-VDM-AUS-0304 Zest/PFISY1978

Before prescribing, please review Product Information available from here.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

To monitor outcomes of pregnant women exposed to VYNDAMAX, a Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) program has been established. If a pregnancy occurs in a woman being treated with VYNDAMAX, medical or healthcare professionals are encouraged to report the pregnancy to Pfizer Australia.

PBS information: Authority required. Refer to the PBS Schedule for full authority information.